Alpha Tau to Present First Pancreatic Cancer Data at Major Gastroenterology Conference

summarizeSummary

Alpha Tau Medical announced that clinical trial data for its Alpha DaRT therapy in pancreatic cancer patients has been accepted for its first-ever oral presentation at Digestive Disease Week (DDW) 2026, a premier international gastroenterology conference.

check_boxKey Events

• Oral Presentation Acceptance

  An abstract presenting results from two clinical trials of Alpha DaRT in pancreatic cancer patients has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026.

• First-Ever Pancreatic Cancer Data Presentation

  This marks the first time clinical results of Alpha DaRT in pancreatic cancer patients have been selected for presentation at a major gastroenterology conference, highlighting the potential of the technology for this devastating disease.

• Upcoming Data Disclosure

  The presentation, titled 'Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,' will occur on May 2, 2026, where the full data will be presented.

auto_awesomeAnalysis

Alpha Tau Medical's announcement of an oral presentation for its Alpha DaRT pancreatic cancer data at Digestive Disease Week (DDW) 2026 is a significant positive development. This marks the first time clinical results for Alpha DaRT in pancreatic cancer will be presented at a major gastroenterology conference, indicating growing scientific recognition and potential for the technology in a challenging disease area. While the full data will be presented in May, the acceptance for an oral presentation validates the company's clinical progress and could increase visibility for its innovative alpha-radiation therapy.